Close Menu

NEW YORK – Becton Dickinson announced on Wednesday that it has obtained an expanded indication for a CE Marked immune status assay such that it can now be used to help manage patients with COVID-19. The assay, which is now available in Europe, can be used at hospital admission to determine patients at increased risk of intubation with mechanical ventilation (IMV), and mortality, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.